On August 13, 2025, Plus Therapeutics, Inc. reported its stockholders' equity deficit of $23.6 million, failing the Nasdaq requirement of $2.5 million, leading to a potential delisting, but was granted continued listing subject to meeting financial compliance by August 14, 2025.